ACHV ACHIEVE LIFE SCIENCES, INC.

ACHV financial statements, revenue, balance sheet, cash flow, and SEC filings

CIK: 949858 Exchange: Nasdaq SIC: 2835 (In Vitro & In Vivo Diagnostic Substances) Latest filing: 10-Q filed Aug 11, 2026 Data checked: Oct 21, 2026
Showing 3 of 17 annual and 0 of 64 quarterly periods. Full history available with a free account or via API.

▼ Company Profile

Filer Category
Non-accelerated filer<br>Smaller reporting company
Entity Type
Operating
Public Float
$103.96M (Jun 2025)
Industry (SIC)
2835 In Vitro & In Vivo Diagnostic Substances
Incorporated
DE
Fiscal Year End
December (1231)
Phone
425-686-1500
EIN
954343413
Headquarters
SEATTLE, WA, 98021
Public Float History
Market value of shares held by public investors, reported in annual DEI filings.
Former Names: ONCOGENEX PHARMACEUTICALS, INC. (2008–2017) · SONUS PHARMACEUTICALS INC (1996–2008)

▼ Key Metrics (TTM)

As of Jun 30, 2026
Financials
Revenue
-
Net Income
$-114.04M
Total Assets
$190.44M
Total Equity
$-14.68M
Total Debt
-
Free Cash Flow
-
Ratios
Return on Equity
777.1%
Return on Assets
-59.9%
Current Ratio
0.95x

▼ FY 2025 Summary Analysis

Annual report ending Dec 31, 2025

Overview and Growth

Fiscal 2025 results for ACHIEVE LIFE SCIENCES, INC. included net loss of $54.65M. Diluted earnings per share were -$1.25, translating the period’s attributable earnings into the amount reported for each diluted share. The diluted weighted-average share count was 43.59M, linking total earnings with the per-share result received by shareholders. Diluted shares moved 35.9% from 32.07M in fiscal 2024, leaving the current share base higher year over year. Total assets stood at $41.79M, showing the scale of resources supporting revenue, earnings, liquidity, and financing.

Profitability

After all below-operating-line items, the company recorded a net loss of $54.65M for the fiscal year. The company reported a pretax loss of $54.65M, before the effect of income taxes. The loss-to-equity relationship was 254.0%, placing the bottom-line deficit against shareholder capital. The net loss equaled 130.8% of period-end assets, showing the deficit relative to the asset base. The net loss widened to $54.65M from $39.83M in fiscal 2024.

Liquidity and Capital Structure

The company held $41.79M of assets against $20.27M of liabilities and $21.52M of equity, revealing how the asset base was financed. Current assets were $39.89M against $9.08M of current liabilities, framing the resources and obligations classified within the near-term balance-sheet horizon. At 4.39x, the current ratio shows that short-term assets were greater than short-term liabilities at period end. The company held $20.93M in cash and equivalents, a narrower liquidity measure than total current assets. The cash balance equaled 230.4% of current liabilities, showing how much near-term coverage came from cash alone. The equity-to-assets relationship was 51.5%, placing book capital against the total resource base. Liabilities represented 48.5% of total assets, quantifying the liability-funded share of the company’s resource base. Measured against total assets, cash and equivalents represented 50.1%, a balance-sheet composition measure rather than a liquidity forecast. Total assets were 8.2% higher than fiscal 2024 assets of $38.63M, measuring the company’s own balance-sheet change. Against $20.90M of equity in fiscal 2024, the current book-equity balance moved 3.0% and ended higher. The reported cash balance changed 64.1% from $12.75M in fiscal 2024, ending higher year over year.

Cash Flow and Earnings Quality

The company reported an operating cash outflow of $49.47M, rather than cash generation from operations. Capital spending of $3.00K added to the period’s operating cash use, reinforcing the overall cash deficit after investment for the year. Negative free cash flow was $49.47M, leaving a cash deficit after capital spending and reducing financial flexibility. The cash deficit after capital spending represented 118.4% of the period-end asset base. The operating cash outflow widened to $49.47M from $29.77M in fiscal 2024.
Based on the annual report for the fiscal year ending Dec 31, 2025. Analysis generated .
Sources and calculation details

Reported values are preserved. Derived values use the listed inputs; unavailable inputs remain blank.

Field-level sources for this historical record are unavailable until it is rebuilt from SEC facts.

Annual financial statements for ACHIEVE LIFE SCIENCES, INC.
Metric FY2025 📄 FY2024 📄 FY2023 📄
Income Statement
REVENUE
OPERATING EXPENSES
R&D Expense - $22.82M $15.81M
SG&A Expense - $16.25M $11.44M
NON-OPERATING INCOME / EXPENSE
Interest Expense - - $2.85M
Interest Income $1.50M $2.36M $825.00K
Other Income/Expense $-36.00K $-30.00K $-9.00K
Pretax Income $-54.65M $-39.83M $-29.82M
Net Income $-54.65M $-39.83M $-29.82M
PER SHARE & SUPPLEMENTAL
Diluted EPS $-1.25 $-1.24 $-1.50
Diluted Shares 43.59M 32.07M 19.83M
Depreciation & Amortization $228.00K $229.00K $228.00K
Balance Sheet
ASSETS
Cash & Equivalents $20.93M $12.75M $15.55M
Short-term Investments $15.48M $21.61M -
Other Current Assets - $2.11M $1.33M
Current Assets $39.89M $36.47M $16.98M
PP&E (Net) $3.00K $8.00K $13.00K
Goodwill $1.03M $1.03M $1.03M
Intangible Assets $751.00K $974.00K $1.20M
Other Noncurrent Assets (derived) $113.00K $150.00K $145.00K
Noncurrent Assets $1.90M $2.17M $2.39M
Total Assets $41.79M $38.63M $19.37M
LIABILITIES
Accounts Payable - $1.95M $618.00K
Other Current Liabilities - $573.00K $351.00K
Current Liabilities $9.08M $6.68M $20.81M
Noncurrent Liabilities $11.19M $11.05M $6.00K
Total Liabilities $20.27M $17.73M $20.82M
EQUITY
Common Stock $121.00K $103.00K $90.00K
Additional Paid-in Capital $281.61M $226.34M $164.21M
Retained Earnings $-260.23M $-205.58M $-165.75M
Accumulated OCI $10.00K $31.00K $4.00K
Total Equity $21.52M $20.90M $-1.45M
Total Liabilities & Equity $41.79M $38.63M $19.37M
SUPPLEMENTAL
Shares Outstanding 53.23M 34.69M 21.17M
Check: A − (L + E + Temp. Equity) - - -
Cash Flow Statement
Cash from Operations $-49.47M $-29.77M $-24.48M
Capital Expenditures $3.00K - $21.00K
Cash from Investing $6.11M $-21.58M $-21.00K
Cash from Financing $51.53M $48.53M $15.28M
Free Cash Flow $-49.47M - $-24.50M
Beginning Cash (CFS) $12.77M $15.60M $24.82M
Net Change in Cash $8.17M $-2.82M $-9.22M
Effect of FX on Cash $3.00K $0 $-3.00K
Calculated Ending Cash $20.95M $12.77M $15.60M
Cash per BS $20.93M $12.75M $15.55M
Cash scope difference (CFS − BS) $20.00K $20.00K $50.00K
Cash per CFS $20.95M $12.77M $15.60M

Create a free account to see full history, quarterly data, charts, CSV downloads, and API access.

Create Free Account Log In
🔒

Quarterly data and charts require a free account

Get access to 8 quarters of data, interactive charts, CSV downloads, and API access.

▼ Frequently Asked Questions

Is ACHIEVE LIFE SCIENCES, INC. profitable?

No. ACHIEVE LIFE SCIENCES, INC. reported $-114.04M in net income for trailing twelve months. Profitability data is based on the company's most recent annual report filed with the SEC.